EUVIMEDEUVIMED entdecken
Crossref

Effects of Supplemented Mediterranean Diets on Plasma-Phospholipid Fatty Acid Profiles and Risk of Cardiovascular Disease after 1 Year of Intervention in the PREDIMED Trial

Cristina Razquin, Miguel Ruiz-Canela iD, Andreas Wernitz, Estefania Toledo, Dolores Corella, Ángel Alonso-Gómez, Montse Fitó, Enrique Gómez-Gracia, Ramón Estruch iD, Miquel Fiol, José Lapetra, Lluis Serra-Majem und 5 weitere

Clinical Chemistry · 2023

DOI: 10.1093/clinchem/hvac221 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Chemistry, 2023. Verfasst von Cristina Razquin und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Preventive Medicine and Public Health, University of Navarra, IdiSNA, Pamplona, Spain. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Diet, Mediterranean. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: European Commission, German Federal Ministry of Education and Research, Nutrition and Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Plasma fatty acids (FAs) have been associated with cardiovascular disease (CVD) risk. Diet and endogenous metabolism influence the FA profile of the plasma phospholipid (PL) fraction. In the PREDIMED trial, we examined 1-year changes in the FA profile of plasma PL according to a nutritional intervention with Mediterranean diets, either supplemented with extra-virgin olive oil (MedDiet + EVOO) or mixed nuts (MedDiet + nuts), in a high cardiovascular risk population. We also analyzed if 1-year changes in PL FAs were associated with subsequent cardiovascular risk.

Methods

We included 779 participants in our case-cohort study: 185 incident cases and 594 participants in the subcohort (including 31 overlapping cases). The end point was the incidence of CVD. We measured the FAs of plasma PL at baseline and after 1 year of intervention.

Results

MedDiet + EVOO increased C17:0 and C20:3n9 in linear regression models [β coefficientperSD : 0.215 (95% CI, 0.032–0.399) and 0.271 (0.107–0.434), respectively] and decreased 16:1n7 and C22:4n6 [βperSD: −0.239 (95% CI, −0.416 to −0.061) and −0.287 (95% CI, −0.460 to −0.113), respectively] vs the control group. MedDiet + nuts increased C18:3n3 [βperSD: 0.382 (95% CI, 0.225 – 0.539)], C18:2n6 [βper SD: 0.250 (95% CI, 0.073 — 0.428)], C18:0 [βperSD: 0.268 (95% CI, 0.085—0.452)], and C22:0 [βper SD: 0.216 (95% CI, 0.031—0.402)]; and decreased the sum of six n6 FAs [βper SD: −0.147 (95% CI, −0.268 to −0.027)] vs the control group. The 1-year increase in C18:2n6 was inversely associated with the subsequent CVD risk (HRperSD: 0.64 (95% CI, 0.44–0.92)).

Conclusions

MedDiet interventions changed n6 FAs and C16:1n7c; other changes were specific for each group: MedDiet + EVOO increased C17:0 and C20:3n9, and MedDiet + Nuts C18:3n3, C18:2n6, C18:0, and C22:0 FAs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesDiet, MediterraneanHumansFatty AcidsCohort StudiesRisk FactorsPhospholipids

Stichwörter der Autor:innen

Mediterranean dietPREDIMEDcardiovascular riskfatty acidsphospholipid fraction

Substanzen

Fatty AcidsPhospholipids

Autor:innen und Institutionen

  • Department of Preventive Medicine and Public Health, University of Navarra, IdiSNA, Pamplona, Spain.
  • Centro de Investigación Biomédica En Red (CIBER), M.P. Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.
  • Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
  • Department of Preventive Medicine, Universidad de Valencia, Valencia, Spain.
  • Department of Cardiology, Hospital Universitario de Álava, Vitoria, Spain.
  • Unit of Cardiovascular Risk and Nutrition, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.

ORCID-Profile: Miguel Ruiz-Canela, Ramón Estruch, Jordi Salas-Salvadó, Matthias B Schulze

Förderung

  • European Commission
  • German Federal Ministry of Education and Research
  • Nutrition and Health
  • National Institutes of Health
  • Instituto de Salud Carlos III
  • Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición
  • Centro Nacional de Investigaciones Cardiovasculares
  • Fondo de Investigación Sanitaria–Fondo Europeo de Desarrollo Regional

Zitieren

APA

Razquin, C., Ruiz-Canela, M., Wernitz, A., Toledo, E., Corella, D., Alonso-Gómez, Á., Fitó, M., Gómez-Gracia, E., Estruch, R., Fiol, M., Lapetra, J., Serra-Majem, L., Ros, E., Arós, F., Salas-Salvadó, J., Schulze, M. B., & Martinez-Gonzalez, M. A. (2023). Effects of Supplemented Mediterranean Diets on Plasma-Phospholipid Fatty Acid Profiles and Risk of Cardiovascular Disease after 1 Year of Intervention in the PREDIMED Trial. Clinical Chemistry. https://doi.org/10.1093/clinchem/hvac221

Vancouver

Razquin C, Ruiz-Canela M, Wernitz A, Toledo E, Corella D, Alonso-Gómez Á, et al. Effects of Supplemented Mediterranean Diets on Plasma-Phospholipid Fatty Acid Profiles and Risk of Cardiovascular Disease after 1 Year of Intervention in the PREDIMED Trial. Clinical Chemistry. 2023. doi:10.1093/clinchem/hvac221

BibTeX
@article{Razquin2023,
  author = {Razquin, Cristina and Ruiz-Canela, Miguel and Wernitz, Andreas and Toledo, Estefania and Corella, Dolores and Alonso-Gómez, Ángel and Fitó, Montse and Gómez-Gracia, Enrique and Estruch, Ramón and Fiol, Miquel and Lapetra, José and Serra-Majem, Lluis and Ros, Emilio and Arós, Fernando and Salas-Salvadó, Jordi and Schulze, Matthias B and Martinez-Gonzalez, Miguel A},
  title = {Effects of Supplemented Mediterranean Diets on Plasma-Phospholipid Fatty Acid Profiles and Risk of Cardiovascular Disease after 1 Year of Intervention in the PREDIMED Trial},
  journal = {Clinical Chemistry},
  year = {2023},
  doi = {10.1093/clinchem/hvac221}
}
Kostenlos starten →